Key information

🔎 Fund Overview

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. The Company’s commercial portfolio of branded products focuses on three areas: neurology, rheumatology, and pain and inflammation. Its primary marketed products include INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Otrexup (methotrexate) injection for subcutaneous use, Sympazan (clobazam) oral film, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipso (diclofenac potassium) Liquid filled capsules. Its other commercially available products include OXAYDO (oxycodone HCI, USP) tablets for oral use. INDOCIN (indomethacin) Suppositories are nonsteroidal anti-inflammatory drug (NSAID), indicated for moderate to severe rheumatoid arthritis, including acute flares of chronic diseases, moderate to severe ankylosing spondylitis, acute gouty arthritis and others.